Future Implications for CAR T in Early RRMM and Treatment Sequencing

EP: 1.A 60-Year-Old Man With Early Relapse Multiple Myeloma

EP: 2.Identification, Evaluation, and Management of High-Risk Disease in Early R/R MM

EP: 3.Overview of Referral of CAR T for Early R/R Multiple Myeloma

EP: 4.CARTITUDE-4: Latest Data of Cilta-Cel for Early R/R MM

EP: 5.Navigating Early versus Late Toxicities with CAR T in Myeloma

EP: 6.Alternative Clinical Approaches and Data for Patients not Suitable for 2L CAR T

Now Viewing

EP: 7.Future Implications for CAR T in Early RRMM and Treatment Sequencing

Video content above is prompted by the following:

• What is the future treatment landscape for early relapsed/refractory multiple myeloma (R/R MM)?
• What are the future implications for a patient’s access to care and the role of community providers in the future landscape?
• How do the emerging data impact your approach to treatment sequencing for the next lines of therapy in R/R MM?